The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).

Authors

Pedro C. Barata

Tulane University, New Orleans, LA

Pedro C. Barata , Ella X. Du , Hongbo Yang , Chunyi Xu , Helen Guo , Caroline Cui , Jonathan Nazari , Alexander Niyazov

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).

First Author: Johann S. De Bono

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A four-tier classification system for studying homologous recombination repair gene reversion mutations as a mechanism of resistance to PARP inhibitors and platinum chemotherapy.

First Author: Qiuxiang Ou

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).

First Author: Pedro C. Barata

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).

First Author: Neeraj Agarwal